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ABSTRACT 
 
 
 
Studies towards the Total Synthesis of the Macrocyclic  
Diamine Alkaloid Haliclonacyclamine C. 
(August 2004) 
Tao Qu, B.S., Peking University 
Chair of Advisory Committee: Dr. Gary A. Sulikowski 
 
 
 Marine sponges produce a series of complex polycyclic diamine alkaloids which 
appear to have a common biogenesis from simple bis-pyridine macrocycles.  These 
structurally novel secondary metabolites are presumably biosynthetically produced by the 
controlled ionic coupling of macrocyclic 3-alkyl piperidines leading to 3,4’-linked bis-
piperidines (ii).  Included among these diamine marine alkaloids is haliclonacyclamine C 
(i) which serves as our synthetic target. 
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 Chapter I in this thesis provides background information describing biological 
activity and proposed biosynthetic pathways to these important diamine marine alkaloids.  
Chapter II details progress towards the total synthesis of haliclonacyclamine C.  The 
focus of Chapter II will be on our successful construction of the 3,4’-linked bispiperidine 
central core (ii) highlighted by the use of palladium-mediated C-C bond forming 
processes.  The stereoselective hydrogenation of a coupled product will also be 
discussed.  
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CHAPTER I 
INTRODUCTION TO MARINE MACROCYCLIC DIAMINE ALKALOIDS: 
SIGNIFICANCE AND BIOSYNTHETIC PATHWAYS 
1.1 Background and Biological Importance of Marine Secondary Metabolites 
            Secondary metabolites are compounds produced by organisms which are 
presumably not directly needed for their normal functions.  There exist many theories 
why organisms produce secondary metabolites.  One popular belief is that “they are used 
to store excess nitrogen for later use”.1  This theory seems to have largely arisen because 
many secondary metabolites contain nitrogen.  Another widely held belief is that “they 
are involved in defense of the organism against threatening organisms and animals”.1  
Some scientists subscribe to neither of these beliefs since many secondary metabolites 
neither contain nitrogen nor do they appear to protect the organism from any predators.  
In contrast to the initial beliefs that the secondary metabolites do not play a significant 
role in the life of an organism, many now believe that, either by lucky coincidence or 
evolutionary necessity, secondary metabolites play a vital role in the life of the producing 
organism.  In addition many secondary metabolites are important in communication 
between individuals of a particular species.  As for the term alkaloid, it is rather a broad 
term which describes natural products which have a basic nitrogen atom.  This is one of 
the largest groups of secondary metabolites and contain an amazing diversity of structure 
and biological activity.1  
 
  This thesis follows the style of the Journal of Organic Chemistry. 
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            The study of secondary metabolites has played a major part in the development of 
organic and medicinal chemistry.  Marine organisms produce a fascinating array of 
structurally novel secondary metabolites, many of which possess potentially significant 
biological activity.  A growing collection of complex and structurally diverse marine 
macrocyclic alkaloids have been isolated from marine sponges in the last two decades, 
that are related to each other by a common biogenetic pathway starting from macrocycles 
composed of 3-alkylpyridine or reduced 3-alkylpyridine units2-4 (Figure 1).  
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Figure 1 Structures of some marine secondary metabolites isolated from marine sponges 
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            The first member of this exclusively sponge-derived alkaloid family was reported 
by Higa5 in 1986 and by Nakamura6 in 1987.  The same compound (1.7) was described 
by both groups, but was given different names: manzamine A (1.7), isolated from a 
Haliclona sp. and keramamine A, obtained from Pellina sp., respectively.  Among related 
marine alkloids identified, in order of increasing structural complexity, are 
cyclostellettamine (1.1), xestopongin (1.2), petrosin (1.3), upenamide (1.4), keramaphidin 
B (1.5), haliclonacyclamine C (1.6), manzamine A (1.7) and sarain A (1.8) (Figure 1). 
 
1.2 Baldwin’s Proposed Biosynthetic Pathway to Manzamine Alkaloids 
 The isolation of manzamine A (1.7), a marine alkaloid possessing a distinctly 
unique and unprecedented structure, elicited the following statement from Higa, “its 
[manzamine A’s] provenance is problematical as there appears to be no obvious 
biogenetic path.”5  This challenging problem was clearly taken as an irresistible 
challenge by Baldwin and coworkers who, in response, published a nonexperimental 
paper outlining a biosynthetic pathway leading to the entire family of manzamine 
alkaloids.7  Their biosynthetic pathway not only revealed the structural symmetry hidden 
within the complex architecture of the manzamine alkaloids, but also provided a 
biosynthetic basis that ties the manzamines to an amazing array of structurally diverse 
and seemingly unrelated marine natural products.  Thus, the unique and seemingly 
unrelated secondary metabolites shown in Figure 1, as we shall see, are proposed to share 
a common biogenetic origin.  
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          The following discussion describes Baldwin and co-workers’ biosynthetic proposal 
for the manzamine alkaloids. Subsequent experimental evidences support their 
hypothesis as well.  
 
1.2.1 Details of Baldwin’s Biosynthetic Proposal 
 The group of manzamine alkaloids contains three structural types, represented by 
manzamine A (1.7)5, B (1.9) and C (1.10)8-9 (Figure 2). 
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Figure 2 Structures of manzamines A-C  
 
 Manzamine C (1.10), the least complicated alkaloid of this group, can be reduced 
to four simple units, tryptophan (1.11), a C3 unit (acrolein) (1.12), a C10 unit (a 
symmetrical dialdehyde) (1.13) and ammonia (Scheme 1). Condensation of these units 
would in principle give manzamine C (1.10). 
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Scheme 1 Biogenetic origin of manzamine C proposed by Baldwin 
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            The biosynthesis of manzamine B (1.10) is likely to start with protonation of bis-
dihydropyridine (1.14), derived from two acrolein units (1.12), two symmetrical 
dialdehyde units (1.13) and two ammonia units (Scheme 2).  Intramolecular Diels-Alder 
cycloaddition of 1.15 leads to an advanced intermediate 1.16 with the correct relative 
stereochemistry and connectivity following from the expected endo and regiochemical 
preference of this cycloaddition.  Redox exchange of 1.16 gives immonium species 1.17, 
which is hydrolyzed to an aldehyde 1.18.  Finally, condensation of tryptophan (1.11) and 
1.18 furnishes manzamine B (1.9). 
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Scheme 2 Biogenic origin of manzamine B proposed by Baldwin 
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            Having described the biosynthesis of manzamine B, only three steps are required 
to convert manzamine B to manzamine A (1.7) (Scheme 3).  First, epoxide rearrangement 
of 1.9 generates intermediate 1.19.  Then carbon-carbon double bond isomerization 
followed by allylic oxidation gives intermediate 1.20, which is cyclized to provide the 
manzamine A (1.7).  Notably, saturated macrocyclic bis-piperidine intermediates related 
to 1.15 had earlier been proposed by Cimino and co-workers to serve as biosynthetic 
precursors to xestopongin (1.2), petrosin (1.3) and sarain (1.8) alkaloids (Figure 1).10 
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Scheme 3 Biogenetic origin of manzamine A proposed by Baldwin 
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1.2.2 Other Marine Natural Products Isolated Supporting Baldwin’s Biosynthetic  
         Proposal  
 Since the publication of Baldwin’s hypothesis, a growing number of manzamine 
alkaloids have been isolated from various species of sponge worldwide supporting the 
biosynthetic pathways to the marine sponge secondary metabolites summarized in 
Scheme 2.  For example, the cyclostellettamines A-F (1.1) isolated from the marine 
sponge stelletta sp. in 1994 represent oxidized versions of the proposed intermediate 1.15 
(Figure 3) presented in Baldwin’s proposal described in Scheme 2.  Another example is 
keramaphidin B (1.5), which was independently isolated by both the Kobayashi and 
Anderson groups.11,12  Structurally keramaphidin B (1.5) is the reduced form of the 
proposed cycloadduct (1.16) shown in the Baldwin’s manzamine biosynthetic hypothesis.  
Other isolated natural products include ircinal B (1.21), which resembles the proposed 
intermediate 1.18. 
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Figure 3 Similarity between natural products and intermediates in Baldwin’s proposal 
 
1.2.3 Experimental Evidence Supporting Baldwin’s Proposal 
            To date, no in vivo (i.e. labeling studies) have been described to support the 
proposed biosynthetic pathways outlined in Scheme 2.  However, in 1998 Baldwin and 
Whitehead pursued a biomimetic approach to the manzamine alkaloids focusing on the 
presumed Diels-Alder cycloaddition step (Scheme 4).13,14  The synthesis of 1.24 was 
accomplished via a five-step reaction sequence starting from hydroxyphosphonium salt 
1.22 and 3-(3-pyridyl)propanal 1.23. Oxidation of 1.24 with m-CPBA furnished a 
mixture of N-oxides, which were treated with trifluoroacetic anhydride to give bis-
dihydropyridine 1.25.  It was eventually discovered that dissolution of 1.25 in an aqueous 
methanol buffer, followed by reduction, yielded a very small but detectable amount of 
cycloadduct keramaphidin B (1.5) within a complex mixture of products.  Although the 
yield of the key reaction Diels-Alder cycloaddition was very low (0.2 – 0.3% yield), 
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Baldwin and co-workers have demonstrated the chemical feasibility of their theoretical 
proposal for the biogenetic origin of the manzamine alkaloids. 
 
Scheme 4 Baldwin’s biomimetic approach to keramaphidin B    
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1.3 Biosynthetic Pathway to Haliclonacyclamine C 
            By analogy to the Baldwin and Whitehead proposal, we suggest a biosynthetic 
pathway to haliclonacyclamine C (1.6) (Scheme 5).  In our proposal, condensation of an 
unsaturated dialdehyde 1.26, a saturated dialdehyde 1.25, two molecules of acrolein 1.12 
and two molecules of ammonia produce a partially reduced bis-3-alkylpyridine 
macrocycle 1.27, which sets the stage for a key intramolecular Diels-Alder cyclization 
leading to the natural product haliclonacyclamine C.  This cyclization establishes the 
correct relationship between the two hydrogens on the central carbon-carbon bond 
linking the two piperidine rings.  
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Scheme 5 Proposed biosynthetic pathway to haliclonacyclamine C 
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1.4 Marazano’s Modification of Baldwin’s Proposal 
 Recently, results from Marazano’s laboratory have prompted them to introduce a 
modification of the original Baldwin’s proposal for the biosynthesis of manzamine 
alkaloids (Scheme 6).15,16  In their new model, they replaced acrolein unit in Baldwin’s 
proposal with malonaldehyde 1.30.  Thus, condensation of malonaldehyde with another 
aldehyde and a primary amine produces the key intermediate aminopentadienal 
derivatives (two possible regio-isomers 1.31 and 1.32) that have been shown17 to be 
prone to cyclization to give 3-alkyl pyridinium salt 1.33.  These aminopentadienal 
derivatives not only produce pyridinium salts, but also could alternatively undergo a 
Diels-Alder cycloaddition with dihydropyridinium salt 1.34. 
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Scheme 6 Marazano’s modification of Baldwin’s proposal 
                   
O
O
NH2
N
O
N
OH
N
+ HX
- H2O
O
O
O
NH2
HN
O
HN O
or
N
+ HX
- H2O
Baldwin and Whitehead's Proposal
Marazano's Modified Proposal
1.30
1.31 1.32 1.33
1.34
 
 
            On the basis of this chemistry, Marazano and co-workers put forward a modified 
biogenetic pathway to the manzamine alkaloids (Scheme 7).  In this new model, 
macrocycle 1.35, possessing both dihydropyridinium and aminopentadienal moieties, 
undergoes an intramolecular Diels-Alder reaction to give cycloadduct 1.36, an advanced 
intermediate in the biosynthesis of manzamine A and other biogenetically closely related 
marine alkaloids. 
 
Scheme 7 Marazano’s modified biogenetic pathway to manzamine A 
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1.5 Recent Advances in the Biosynthesis of 3-Alkylpyridine 
            As stated above in the Background and Biological Importance section, these 
structurally diverse marine macrocyclic alkaloids are related to each other by a common 
biogenetic pathway starting from macrocycles composed of 3-alkylpyridine or reduced 3-
alkylpyridine units.  Therefore, the origin of the 3-alkylpyridine is one of the key issues 
to be addressed in the understanding of the biosynthetic pathway to these complex 
marine alkaloids.  As already proposed by Baldwin and Whitehead in their biogenetic 
pathway to manzamine alkaloids, the 3-alkylpyridine motif originated from the 
condensation of three simple units: ammonia, a C10 unit (an unsaturated dialdehyde) and 
a C3 unit (acrolein) (Scheme 2).  However, to date there has been no in vivo evidence 
(i.e. labeling studies) to support Baldwin’s proposed biosynthetic pathway to 3-
alkylpyridine, the precursor of these macrocyclic marine alkaloids including some of the 
most intriguing structures ever isolated from marine organisms, such as sarains and 
manzamines.   
            Most recently, Fontana and his group in Italy described the first in vivo evidence 
concerning the biosynthesis of 3-alkylpyridines in marine organisms.18,19  They have 
pursued feeding experiments to elucidate a polyketide biosynthetic pathway leading to an 
alkylpyridine alkaloid, haminol-2 (1.37) (Scheme 8) which was isolated from the 
Mediterranean mollusc Haminoea orbignyana.  Two preliminary experiments were 
carried out by feeding the mollusk H. orbignyana with either radio-labelled [2-14C]-acetic 
acid and or nicotinic acid-carboxy-14C and after injection, they found significant levels of 
radioactivity in haminol-2 (1.37) produced by this animal.  In this way, they proved de 
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novo origin of haminols.  In order to fully understand the biosynthesis of haminol-2 
(1.37) in H. orbignyana, some other experiments were also performed by injecting the 
animal with either d4-nicotinic acid ethyl ester or [1-13C]-acetic acid.  By means of 
extensive feeding experiments with 13C or 14C labeled acetate and nicotinic acid, and 
subsequent spectral studies, they proved the origin of haminol-2 (1.37) via a polyketide 
synthase (PKS) using nicotinic acid (1.38) as a starter unit and six molecules of acetate 
(or the metabolically equivalent malonate) as extender units (Scheme 8).18  Loss of the 
terminal carbon of the PKS-emerging chain 1.39, presumably due to a post-PKS 
decarboxylation, provides the skeleton 1.40 of haminol-2 (1.37).  Their discovery 
allowed them to “conclude that haminols are produced in H. orbignyana through a 
polyketide pathway and ruled out other hypotheses about the formation of 3-
alkylpyridine framework”.19  However, their studies cannot exclude that the biosynthesis 
of more complex marine alkaloids, such as manzamines and sarains follow other 
biochemical mechanisms.  
 
Scheme 8 Proposal for the biosynthesis of 1.37 based on feeding experiments 
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CHAPTER II 
PROGRESS TOWARDS THE TOTAL SYNTHESIS OF THE TETRACYCLIC  
DIAMINE ALKALOID HALICLONACYCLAMINE C 
2.1 Haliclonacyclamines: Isolation, Structure and Biological Activity 
 As discussed in Chapter I, cytotoxic alkaloids containing a 3-alkyl pyridine or 
piperidine motif have been frequently isolated from marine sponges.  This group of 
marine secondary metabolites can be subdivided into tricyclic, tetracyclic or pentacyclic 
alkaloids.  The manzamine class of alkaloids represent a complex structural variation 
within this group which incorporates a tetra- or pentacyclic system fused to a β-carboline 
unit.20  In this chapter, we will describe progress towards the chemical synthesis of the 
tetracyclic haliclonacyclamine family (Figure 4). 
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Figure 4 Structures of haliclonacyclamines A-D 
 
            Haliclonacyclamines A (2.1) and B (2.2) were isolated from the olive-brown 
finger sponge Haliclona sp. collected at Heron Island, Great Barrier Reef in 1996 by 
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Garson and co-workers.21  The same research group isolated haliclonacyclamines C (2.3) 
and D (2.4) from the same sponge in 1998.20  The structures of haliclonacyclamines C 
and D are dihydro derivatives of haliclonacyclamines A and B respectively.  Structures of 
the haliclonacyclamines were elucidated by extensive NMR studies and X-ray structural 
analysis in the case of haliclonacyclamine B (2.2). 
            The tetracyclic haliclonacyclamines show pronounced cytotoxic, antibacterial and 
antifungal activities.  For example, haliclonacyclamine C has an IC50 value of 0.7 µg/mL 
obtained in a P388 assay, and also displays antibacterial activity towards Bacillus subtilis 
and strong antifungal activity against Candida albicans and Trichophyton 
mentagrophytes.20 
 
2.2 Retrosynthetic Analysis of Haliclonacyclamine C 
 Although the proposed biosynthesis of haliclonacyclamine C (2.3) and its 
relationship to the biosynthesis of other related marine secondary metabolites are 
fascinating, we chose to engage in the synthesis of haliclonacyclamine C from a purely 
classical chemical approach (For a proposed biomimetic synthesis of haliclonacyclamine 
C see Chapter I).  The common structural feature shared by this group of secondary 
metabolites is a reduced bis-piperidine core structure combined with two bridging 
macrocycles.  Two examples, haliclonacyclamine C (2.3) and arenosclerin B (2.5) 
illustrate a common tetracyclic structural motif possessing a 3,4’-linked bis-piperidine 
core (Figure 5).  The primary structural variations within this group of secondary 
metabolites occur in the stereochemistry of the core bis-piperidine structure and the 
  
16
oxidation state of two bridging macrocycles.  For example, haliclonacyclamine C has 
only one site of unsaturation while arenosclerin B has three sites of unsaturation and an 
allylic hydroxyl group of undefined stereochemistry located at C(22).  More subtle 
differences in structure occur in the relative stereochemistry of stereogenic centers 
arranged within the bis-piperidine ring system.  In the case of haliclonacyclamine C (2.3) 
and arenosclerin B (2.5), they share common stereochemistry at C(7) and C(9) but differ 
in configuration at C(2) and C(3).  One of our key transformations to be addressed in the 
synthesis of haliclonacyclamine C is a palladium-mediated cross-coupling to generate the 
core bis-piperidine structure by formation of the C(3)-C(9) carbon-carbon bond.  We also 
judge control of the four stereocenters that are incorporated within the central bis-
piperidine to be synthetically challenging, particularly the relative stereochemistry of the 
central carbon-carbon bond that links the two piperidine units. 
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Figure 5 Structures of haliclonacyclamine C and arenosclerin B 
 
            A retrosynthetic analysis of haliclonacyclamine C is shown in Figure 6.  The 
stereoselective hydrogenation of diene 2.6 will be the key transformation to give a bis-
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piperidine unit incorporating the correct relative stereochemistry common to the natural 
product haliclonacyclamine C (2.3).   
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Figure 6 Retrosynthetic analysis of haliclonacyclamine C 
 
            This prediction is based on examination of molecular mechanics modeling of 2.11 
(Figure 7).  Using MMFF94 force field and water GB/SA solvent model in Macromodel, 
a Monte-Carlo global minimization of 2.11 is applied to obtain the optimized geometry.  
The four lowest energy conformations are shown in Figure 7.  It can be clearly seen that 
the molecular model of 2.11 shows the macrocyclic ring effectively blocks one face of 
ring B, thus favoring hydrogenation from the other face of ring B.  Also it should be 
noted that the alkyl chain on C2 in ring B will block the bottom face of ring A, thus 
hydrogenation will take place on the top face of ring A.  Based on this analysis we 
predict the production of the relative stereochemistry found in haliclonacyclamine C.  
Dienes 2.6 could be synthesized from intramolecular cyclization of intermediate 2.7 
(Figure 6).  Palladium-mediated coupling of beta-iodo enecarbamate 2.8 and 2.9 (Heck 
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reaction) or 2.10 (Stille raction) would be investigated as a key reaction to construct the 
bis-piperidine core structure 2.7 in the total synthesis. 
 
   
N
NBoc
MeO2C
O
CH3
AB
2.11
E1 = -36.79 KJ/mol E2 = -33.29 KJ/mol
E3 = -25.82 KJ/mol E4 = -24.42 KJ/mol
A
A
A A
B
B
B
B
 
Figure 7 Molecular modeling of 2.11 (MMFF94 force field in Macromodel) 
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2.3 Model Study of Heck Reaction to Construct 3,4’-Linked Bis-piperidines 
 At the outset, we examined the Heck reaction to construct the 3,4’-linked bis-
piperidines core structure.  We planned to carry out the Heck reaction of beta-iodo 
enecarbamate 2.12 or 2.8 with olefin 2.13 to generate the core structure 2.14 of 
haliclonacyclamine C (Scheme 9). 
 
Scheme 2.1 Model study of Heck reaction to construct 3,4’-linked bis-piperidines 
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2.3.1 Mechanism of Heck Reaction 
            The palladium-catalyzed coupling of an aryl or vinyl halide or triflate with an 
alkene, known as the Heck reaction has undergone tremendous innovation since its first 
report in 1968.22  It has progressed from a simple olefination of activated aryl compounds 
to a powerful method in organic synthesis of natural products.  The catalytic cycle23 of 
this reaction is outlined in Scheme 10. 
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Scheme 10 Mechanism of Heck reaction23 
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           The entry into the catalytic cycle is the reduction of Pd(II) complexes to Pd(0) and 
the generation of active species through a preactivation step which usually includes 
multiple ligand exchange equilibria. Once the active Pd(0) species is formed, the 
oxidative addition step in the catalytic cycle takes place through insertion into an alkenyl 
halide or an aryl halide (R1X) bond to give the 16-electron complex 2.15.  An insertion of 
the olefin into the Pd-C bond after olefin complexation with the 16-electron Pd(II) 
species, generates the intermediate 2.16.  This step is the product-forming step of the 
whole cycle, in which a new C-C bond is generated.  It is noteworthy that this step is 
“most likely responsible for regio- and stereo- discrimination as well as substrate 
selectivity”.24  It also should be pointed out that the step of olefin insertion takes place as 
a syn addition and the palladium complex with bulky organic ligands is likely to be 
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bonded to the less hindered carbon of the olefin in order to avoid any significant steric 
repulsion.  The next step in the Heck cycle involves a simple carbon-carbon bond 
rotation of 2.16 to give 2.17 which orients the palladium species and hydrogen syn to 
each other.  2.17 is ready to undergo a syn beta-hydride elimination to give the final 
coupling product E-alkene 2.19 and the hydridopalladium complex 2.18.  Finally, a base-
induced reductive elimination of HX from 2.18 regenerates the palladium(0) catalyst, 
thus permitting a subsequent turn through the Heck cycle.  
 
2.3.2 Synthesis of Beta-Iodo Enecarbamate 
            With the Heck route to the halicolonacyclamines in mind, we set as our first goal 
the synthesis of beta-iodo enecarbamates 2.12 and 2.8 (Scheme 11).  Endocyclic 
enamides and enecarbamates are important building blocks for the synthesis of alkaloids.  
Generally, two approaches have been explored starting from either lactams or saturated 
amines.  In one approach, enamides and enecarbamates can be produced from lactams via 
a two-step reduction and dehydration sequence.25-27  More recent reports describe the 
conversion of lactams into enol triflate or phosphates that undergo Stille or Suzuki cross-
coupling reactions.  However, we were encouraged by a more economical and easily 
scaleable process, that is anodic methoxylation of lactams28 followed by acid-catalyzed 
elimination of methanol.  For example, electrochemical methoxylation of valerolactam 
2.20 afforded aminal 2.21 in 50% overall yield (Scheme 11).  The iodo group was then 
introduced into the beta position to afford 2.12 using a two-step procedure.  Boc 
protection of 2.12 gave N-protected beta-iodo enecarbamate 2.8 in moderate yield. 
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Scheme 11 Synthesis of beta-iodo enecarbamate 
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2.3.3 First Attempt to Construct 3,4’-Linked Bis-piperidines by Heck Reaction 
            With beta-iodo enecarbamates 2.12 and 2.8 in hand, we were ready to investigate 
the Heck reaction to construct the core structure 3,4’-linked bis-piperidines.  The 
synthesis of the olefin partner 2.28 of the Heck reaction is outlined in Scheme 12. 
Conversion of alcohol 2.24 to amine 2.25 by applying a two-step reaction sequence 
proceeded in almost quantitative yield.29  Double Michael addition of amine 2.25 to 
methyl acrylate generated an intermediate diester which was treated with base NaHMDS 
leading to a Dieckman cyclization and providing beta-keto ester 2.26.  The latter was 
reduced by sodium borohydride to yield beta-hydroxy ester 2.27.  A two-step dehydration 
reaction sequence completed the synthesis of enoate 2.28 in 81% yield. 
 
 
 
  
23
Scheme 12 Synthesis of enoate 2.28 
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           At this stage, we were ready to attempt our palladium-mediated C-C bond 
formation of enoate 2.28 with either vinyl iodide 2.12 or 2.8.  Unfortunately, as seen in 
Table 1, our attempts to construct the central C-C bond by Heck reaction failed to 
produce any of the desired product 2.29.  Frequently, only the isolation of starting 
materials was observed.  
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    Table 1 Heck reaction of vinyl iodide with enoate 2.28 
N
O
OMe
7
2.28
NH
O
I
N
O
I
Boc
2.82.12
or +
N
O
OMe
7
2.29
N
O
R
Reaction Conditions
Entry Vinyl Iodide Catalyst Ligand / Additive Solvent Temp (oC) Result
1
2
3
4
5
6
2.12
2.12
2.12
2.8
2.8
2.8
Pd(OAc)2
Pd(OAc)2
Pd(OAc)2
Pd2(dba)3
Pd2(dba)3
DMF
CH3CN
THF
CH3CN
DMA
DMF 60
60
25
60
80
80
PPh3, Na2CO3
PPh3, Et3N
PPh3, Ag2CO3
BINAP, Ag2CO3
dppe, Et3N
NaHCO3, n-Bu4NCl, 
4A MS
2.12 decomposed, 2.28 recovered
2.12 patially decomposed, 2.28 recovered
2.12 decomposed, 2.28 recovered
Unknown compound
2.8 and 2.28 recovered
2.8 decomposed, 2.28 recoveredPd(OAc)2
 
 
            Interestingly, when we replaced vinyl iodide 2.12 or 2.8 with iodobenzene 
(Scheme 13), the Heck reaction did proceed to give coupled product 2.30 under Jeffery’s 
condition30.  However, 2.30 was not the product we desired.  Instead of reacting with the 
enoate alkene, iodobenzene reacted with the terminal olefin of 2.28 to give undesired 
coupled product 2.30.  
 
Scheme 13 Heck reaction of iodobenzene with enoate 2.28  
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            In order to test the reactivity of the beta-iodo enecarbamate partner 2.8, we 
conducted a model study on the Heck reaction of 2.8 and ethyl acrylate.  It was found that 
under Jeffery’s condition,30 the Heck coupled product 2.31 was generated in good yield 
(Scheme 14).  At this stage, we were confident that the oxidative addition of active Pd(0) 
species to the carbon-iodine bond did take place, which is the first step in the Heck 
catalytic cycle. 
 
Scheme 14 Heck reaction of beta-iodo enecarbamate 2.8 and ethyl acrylate  
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2.3.4 Second Attempt to Construct 3,4’-Linked Bis-piperidines by Heck Reaction 
            Since the reactivity of the beta-iodo enecarbamate proved not to be a problem 
from our model study (Scheme 14), we reasoned that the failure is due to the electron-
rich terminal olefin competing with the electron-deficient enoate olefin within the 
piperidine ring in the olefin insertion step in the Heck catalytic cycle (Scheme 10).   We 
therefore chose to examine enoate 2.36, which has no other sites of unsaturation.  The 
synthesis began with Boc protection of 4-piperidone 2.32 to give 2.33, which was treated 
with LHMDS followed by quenching with methyl cyanoformate (Mander’s reagent) to 
generate beta-keto ester 2.34 (Scheme 15).  Enoate 2.36 was obtained in good yield by 
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using a three-step reaction sequence we developed in the synthsis of enoate 2.28 (Scheme 
12). 
 
Scheme 15 Synthesis of enoate 2.36 
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            To our delight, Heck coupling of iodobenzene and the modified olefin 2.36 
proceeded to give the desired product 2.37 under Jeffery’s condition (Scheme 16).  
However, under a variety of reaction conditions, beta-iodo enecarbamate 2.8 failed to 
couple with olefin 2.36.  The lack of reactivity of this Heck reaction is probably due to 
the steric hindrance of the tri-substituted olefin partner, which makes it difficult to 
undergo olefin insertion to the R-Pd-I complex, the product-forming step in the Heck 
catalytic cycle (Scheme 10).  
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Scheme 16 Heck reaction of olefin 2.36 
N
O
Boc
I
+
2.8
N
O
OCH3
Boc
N
O
Boc
N
CO2CH3
Boc
2.36 2.38
N
O
OCH3
Boc
2.36
Ph
N
CO2CH3
Boc
2.37
I +
Pd(OAc)2, NaHCO3, n-Bu4NCl
4A MS, DMF, 70 oC
25%
 
 
2.4 Model Study of Stille Coupling to Construct 3,4’-Linked Bis-piperidines 
            We now turn our attention to the application of Stille coupling to construct the 
core structure 3,4’-linked bispiperidines (Scheme 17).  
 
Scheme 17 Model study of Stille coupling to construct 3,4’-linked bis-piperidines 
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2.4.1 Mechanism of Stille Coupling 
            Alkenyltins undergo a palladium-mediated coupling with a wide variety of 
organic halides and triflates.  The high yields and mild reaction conditions of this 
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reaction have been led to much success in natural product synthesis.  An additional virtue 
of this palladium-mediated coupling reaction is that a variety of functional groups (e.g. 
CO2R, CN, OH) can be tolerated.  A catalytic cycle of the so-called Stille cross-coupling 
is described in Scheme 18.23  In the catalytic cycle, a coordinatively unsaturated 14-
electron palladium(0) complex is generated as the catalytically active species.  The first 
step in the catalytic cycle is an oxidative addition of the organic eletrophile R-X to the 
palladium(0) catalyst leading to a 16-electron palladium(II) complex 2.40.  Then 2.40 
participates in a transmetalation step with the organotin reagent R1-Sn(R2)3 to give a new 
palladium complex 2.41.  After facile isomerization of trans isomer 2.41 to cis isomer 
2.42, a reductive elimination releases the cross-coupled product R-R1 and regenerates the 
active palladium(0) complex allowing for another catalytic cycle. 
 
Scheme 18 Mechanism of Stille coupling23 
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2.4.2 Synthesis of Vinyl Stannane 2.44 
            The synthesis of Stille coupling reaction partner vinyl stannane 2.44 started from 
beta-keto ester 2.34 (Scheme 19).  Treatment of 2.34 with base KHMDS followed by the 
addition of Comins’ reagent31 generated the vinyl triflate 2.43 in excellent yield.  
Conversion of vinyl triflate 2.43 to vinyl stannane 2.44 under Wulff conditions32 
(Me6Sn2, Pd(PPh3)4, LiCl, THF) did not afford any desired product.  To our delight, 
higher-order stannyl cuprate33 addition to the vinyl triflate furnished vinyl stannane 2.44.  
 
Scheme 19 Synthesis of vinyl stannane 2.44 
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2.4.3 Stille Coupling to Construct 3,4’-Linked Bis-piperidine Core Structure 
            Next, we turned our attention to the Stille coupling of the two components 2.44 
and 2.12.  It has been well-known that a major limitation of Stille coupling reactions 
arises from steric hinderance, especially in the vinyl stannane component.  So there was 
some concern regarding the steric congestion of the vinyl stannane 2.44.  Indeed, our 
initial attempts to construct the central C-C bond by traditional Stille cross-coupling 
conditions either failed to produce any of the desired diene 2.45 (Scheme 20) or did not 
afford significant quantities of the desired product.  At this juncture, we were intrigued 
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by a report from Corey and co-workers detailing the superiority of using CuCl rather than 
other Cu(I) salts as an additive in the Stille cross-coupling reaction of vinyl/aryl halides 
or triflates.34  We were pleased to find that implementation of the Corey procedure 
(rigorous exclusion of oxygen and moisture) resulted in smooth conversion of vinyl 
stannane 2.44 to the desired diene 2.45 in good yield as illustrated in Scheme 20.  It is 
believed that the function of CuCl is to convert the vinylstannane to a more reactive 
vinylcopper(I) species, thus to facilitate the transmetallation step in the catalytic cycle of 
Stille coupling reactions. 
 
Scheme 20 Stille coupling of 2.12 and 2.44 
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2.4.4 Stereoselective Hydrogenation of Diene 2.45 
            Pleased with our ability to obtain diene 2.45 in synthetically useful amounts, we 
now turned our attention to establishing the requisite stereochemistry across the central 
C-C bond by a heterogeneous hydrogenation as illustrated in Scheme 21.  In principle, 
there are four possible diastereomers produced from the reduction of 2.45.  The 500 MHz 
1H-NMR spectrum of the hydrogenation product 2.46 was not well resolved (Figure 8), 
perhaps due to isomers as well as rotamers originating from the Boc group on the 
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nitrogen.  Interestingly, when we analyzed the hydrogenated product 2.46 using Gas 
Chromatography (GC), only one product was indicated.   
 
Scheme 21 Hydrogenation of diene 2.45 
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            To our delight, when we applied the method of VT-NMR (75 oC, solvent: 
(CD3)2SO) to analyze the compound, the spectrum clearly showed the hydrogenated 
product 2.46 coalescent to a single diastereomer (Figure 8).  It is also noteworthy that 
when running the hydrogenation of diene 2.45, we did isolate a byproduct that we believe 
was the partially reduced product 2.47 (Scheme 21).  In this case, we were a little 
surprised that the tetra-substituted olefin was more easily reduced than the tri-substituted 
olefin.   
 
 
 
 
 
  
32
 
ppm1234567
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Figure 8 Comparison of room temperature and 75 oC 1H-NMR of 2.46 in (CD3)2SO 
room temperature 
75 oC 
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            Conformational analysis of partially reduced product 2.47 by molecular modeling 
in macromodel (MMFF94 force field, water GB/SA model) is shown in Figure 9.  The 
lowest energy conformation from calculation is E1, which energy is -316.66 KJ/mol.  
Figure 9 also shows the next three lowest energy conformations E2, E3 and E4 for 
comparison.  From the molecular modeling of 2.47, we can clearly see that the methyl 
ester group blocks one face of ring A (Figure 9), thus hydrogenation presumably takes 
place from the other face of ring A to generate one single diastereomer.   
            
A
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E3 = -313.02 KJ/mol E4 = -308.78 KJ/mol
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Figure 9 Molecular modeling of 2.47 (MMFF94 force field in Macromodel) 
 
            Based on the above molecular modeling analysis, we predict the hydrogenation 
product to be 2.48 (Scheme 22), the diastereomer of the product 2.49 that we desire.   
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Scheme 22 Predicted hydrogenation product of diene 2.45 
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            In order to determine the relative stereochemistry of the hydrogenation product 
2.46 (Scheme 21), we planned to make crystal derivative of 2.46 and confirm the 
stereochemistry by single crystal X-ray analysis of the derivative.  We attempted to 
funtionalize the lactam nitrogen of 2.46 with aromatic groups that would impart 
crystallinity.  Unfortunately, as seen in Table 2, protection of the nitrogen with 2,4-
dinitrobenzenesulfonyl chloride using several bases did not furnish any desired product 
2.50.  When we used the less hindered p-toluenesulfonyl chloride to protect the lactam 
nitrogen, it still did not yield any desired product.  We were pleased to find that 
protection of 2.46 with 4-bromobenzoyl chloride using sodium hydride as a base gave the 
desired product in good yield.  Unfortunately this derivative is not a crystal that can be 
used for single crystal X-ray analysis.   
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Table 2 Protection of lactam nitrogen of 2.46 
N
Boc
O
OCH3
NH
O
2.46
HH
H
N
Boc
O
OCH3
N
O
2.50
HH
H
R
Entry Protective Group Base Result
1
2
3
4
5
NaH
NaH
n-BuLi
NaHMDS
NaHMDS
2,4-dinitrobenzenesulfonyl chloride
2,4-dinitrobenzenesulfonyl chloride
2,4-dinitrobenzenesulfonyl chloride
4-bromobenzoyl chloride
p-toluenesulfonyl chloride
no desired product 2.50
no desired product 2.50
no desired product 2.50
no desired product 2.50
68% yield of product 2.50, not crystal
Protective Group
Base
 
 
            Now we have turned our attention to making crystal derivative of hydrogenation 
product 2.46 via reduction of the methyl ester to a primary alcohol followed by 
protection of both nitrogen and oxygen with protective groups (Scheme 23).  The 
assignment of relative stereochemistry of 2.46 via experiment is currently under 
investigation.  Once we are able to generate a crystalline derivative of 2.46, we will 
examine our stereochemical prediction of the hydrogenation product 2.46 based on our 
molecular modeling studies.  We believe that it is important for us to understand the 
reason for stereoselective hydrogenation of the diene in terms of future synthetic studies 
towards the total synthesis of this family of macrocyclic diamine alkaloids.    
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Scheme 23 Future work on making crystal derivative of 2.46 
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2.5 Future Directions 
            Currently, our efforts are directed towards the synthesis of vinyl stannane 2.10 as 
depicted in Figure 10 by applying the chemistry we have developed for the synthesis of 
2.26 (Scheme 12) and 2.44 (Scheme 19).  Once we obtain vinyl stannane 2.10, we will 
couple it with beta-iodo enecarbamate 2.11 to give the coupled product 2.8 as described 
in Figure 6.  Since we have developed a general methodology for the preparation of 3,4’-
linked bis-piperidines, work on this project will continue along these lines with the focus 
on stereoselective hydrogenation of the corresponding diene 2.6 (Figure 6) to generate 
the reduced bis-piperidines incorporating the requisite stereochemistry. 
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Figure 10 Synthetic approach to vinyl stannane 2.10 
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            We also examined the conformation of diene 2.45 and compared the dihedral 
angle of C(2)-C(3)-C(9)-C(10) to that in 2.11.  The conformations of 2.45 and 2.11 were 
obtained by a Monte-Carlo global minimization of 2.45 using MMFF94 force field and 
water GB/SA solvent model in Macromodel (Figure 11).  The dihedral angle of C(2)-
C(3)-C(9)-C(10) in 2.11 is 85o, while the same dihedral angle in 2.45 is 66o.  Since we 
have obtained one single diastereomer from the hydrogenation of diene 2.45, we are 
confident in our ability to generate only one diastereomer out of the hydrogenation of 
diene 2.11.  Although we presumably obtained the diastereomer 2.48 with the 
stereochemistry opposite to what we desire in the hydrogenation of diene 2.45 based on 
our molecular modeling studies, we believe that with the macrocycle tethered the two 
piperidine rings and long alkyl chain sitted in the C(2) position, we will be able to obtain 
the desired stereoselective hydrogenation product as we have discussed in the section of 
Retrosynthetic Analysis of Haliclonacyclamine C in this chapter.  
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Figure 11 Molecular modeling of 2.11 and 2.45 (MMFF94 force field in Macromodel) 
 
 
2.6 Experimental Section 
 General Procedures. Reagents were obtained from commercial suppliers, and 
where appropriate were purified prior to use.  All reactions were carried out under a 
nitrogen or argon atmosphere using dry glassware which had been flame-dried under 
vacuum and back filled with argon, unless otherwise noted.  All necessary solvents were 
purified prior to use.  Tetrahydrofuran and ethyl ether were distilled from 
sodium/benzophenone; dichloromethane and benzene were distilled from calcium 
hydride.  Triethylamine was distilled from calcium hydride and stored over sodium 
hydroxide.  Reactions were monitored by thin-layer chromatography (TLC) using 0.25-
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mm E. Merck precoated silica gel plates.  Visualization was accomplished with UV light 
and aqueous ceric ammonium molybdate solution, anisaldehyde stain, or potassium 
permanganate stain followed by charring on a hot-plate.  Flash chromatography was 
performed using silica gel 60 (particle size 230-400 mesh) with the indicated solvent.  
Yields refer to chromatographically and spectroscopically pure compounds unless 
otherwise noted.  Melting points are uncorrected unless otherwise noted.  1H and 13C 
NMR spectra were recorded on Varian 500 MHz spectrometers at ambient temperature, 
unless otherwise noted.  1H and 13C NMR data are reported as δ values relative to 
tetramethylsilane, chloroform, or DMSO.  High-resolution mass spectra were obtained at 
Texas A&M University Mass Spectrometry Service Center by Dr. Shane Tichy on an 
API QSTAR Pulsar Instrument. 
            Molecular modeling studies of compounds 2.11, 2.45 and 2.47 were performed in 
Macromodel using Monte-Carlo global minimization and MMFF94 force field.  Water 
GB/SA model and 1000 steps of structural minimization were applied.  
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            Enamine 2.22.  Valerolactam 2.20 (3.40 g, 34.3 mmol) and tetraethylammonium 
tetrafluoroborate (3.0 g, 13.8 mmol) were added to methanol (100 mL).  The reaction 
vessel was equipped with one graphite-rod anode and one graphite-rod cathode, and a 
magnetic stirring bar.  During the electrolysis, the voltage was 25 V and the current was 
about 0.7 A.  After stirring the reaction at room temperature for 11 h, GC analysis 
showed the starting material disappeared.  The reaction was poured into a mixture of 
diethyl ether (50 mL) and pentane (50 mL).  The mixture was filtered, and concentrated 
in vacuo to get the crude product 2.21.  To a solution of the above crude product 2.21 in 
toluene (100 mL) was added p-toluenesulfonic acid (0.1 g, cat.).  The reaction mixture 
was refluxed for 2 h using a Dean-Stark trap.  The solution was then cooled and the 
solvent was removed in vacuo.  The residue was purified by flash column 
chromatography (3:1 hexanes/EtOAc) to afford 1.66 g (50%, over 2 steps) of enamine 
2.22 as a white solid.  Spectral data correlated with the reported values35. 
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            Beta-iodo Enamine 2.12.  To a sitirred solution of 2.22 (3.64 g, 37.5 mmol) in 
methanol (100 mL) at -78 oC was added dropwise ICl (0.8 M solution in CH2Cl2, 70.4 
mL, 56.3 mmol).  The resulting yellow suspension was stirred at -78 oC for 1 h, after 
which a saturated aqueous solution of Na2S2O3 (50 mL) was added and stirring continued 
for an additional 30 min.  The mixture was extracted with Et2O (3 X 50 mL).  The 
combined organic extracts were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo to give a crude product 2.23 as a yellow oil.   
            To a stirred room temperature solution of the above crude product 2.23 in toluene 
(200 mL) was added trifluoroacetic acid (0.091 mL). The reaction flask was immediately 
lowered into a preheated 145 oC oil bath. The solution was refluxed for 10 min during 
which time the solution turned a dark red color.  The reaction flask was cooled to room 
temperature and transferred to an ice bath.  When the internal temperature reached room 
temperature, triethylamine (0.2 mL) was added and the solvent was removed in vacuo.  
The residue was purified by flash column chromatography (4:1 hexanes/EtOAc) to afford 
2.92 g (35%, over 2 steps) of enamine 2.12 as a light yellow solid.  IR (neat) 3447 broad, 
3201, 3088, 2930, 1670, 1644 cm-1; 1H-NMR (500 MHz, CDCl3) δ 8.29 (s broad, 1H), 
6.44 (dt, J = 4.5, 1.5 Hz, 1H), 2.72 (t, J = 8.0 Hz, 2H), 2.55 (t, J = 7.5 Hz, 2H); 13C-NMR 
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(125 MHz, CDCl3) δ 170.0, 130.9, 68.1, 33.0, 31.7; HRMS (ESI) m/z 229.9642 [(M+Li)+ 
calculated for C5H6INOLi: 229.9654]. 
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            Ketone 2.33.  To a stirred solution of triethylamine (4.52 mL, 32.5 mmol) in 
MeOH (25 mL) was added 4-piperidone monohydrate hydrochloride 2.32 (1.00 g, 6.49 
mmol) and di-tert-butyl dicarbonate (4.48 mL, 19.5 mmol).  The reaction mixture was 
heated at 45 oC for 1.5 h, the solvent was evaporated in vacuo.  2N HCl (10 mL) and 
ethyl acetate (20 mL) were added.  The two phases were separated and the aqueous phase 
was extracted with EtOAc (3 X 10 mL).  The combined organic extracts were dried over 
MgSO4 to give, after evaporation of the solvent, 1.29 g (100%) of pure ketone 2.33 as a 
white solid.  Spectral data correlated with the reported values.36 
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            Beta-keto Ester 2.34.  To a stirred solution of LHMDS (1.73 mL of 1.0M 
solution in tetrahydrofuran, 1.73 mmol) in tetrahydrofuran (8 mL) at –78 oC was added 
was added ketone 2.33 (0.200 g, 1.51 mmol) in tetrahydrofuran (7 mL) dropwise via 
cannula.  The reaction was stirred at –78 oC for 30 min and then quenched with H2O (15 
mL). The two phases were separated and the aqueous phase was extracted with EtOAc (3 
X 10 mL).  The combined organic extracts were dried over MgSO4, filtered, and 
concentrated in vacuo.  The residue was purified by flash column chromatography (15:1 
hexanes/EtOAc) to afford 0.170 g (66%) of beta-keto ester 2.34 as a colorless oil.  
Spectral data correlated with the reported values.37 
 
 
N
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            N-(5-chloro-2-pyridyl)triflimide.38  To a clear solution of 2-amino-5-
chloropyridine (8.0 g, 62.2 mmol) in CH2Cl2 at -78 oC was added pyridine (10.6 mL, 
130.6 mmol).  Then a solution of triflic anhydride (22.0 mL, 130.6 mmol) in CH2Cl2 (50 
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mL) was added dropwise via addition funnel over 3-4 hours at -78 oC.  The reaction was 
stirred at –78 oC for 2 hours, then the cooling bath was removed and stirring was 
continued at room temperature for 19 hours.  The reaction mixture was quenched with 
cold H2O (20 mL) and the layers were separated. The aqueous phase was extracted with 
CH2Cl2 (3 X 20 mL).  The combined organic extracts were washed with 10% NaOH 
solution (60 mL), cold H2O (40 mL), brine (40 mL) and dried over MgSO4.  After 
filtration, the solvent was removed under vacuum to give the crude product.  Vacuum 
distillation of crude product gave 20.2 g of pure N-(5-chloro-2-pyridyl)triflimide (b.p. 
90-95 oC/1.5 mmHg) as a white solid.  Spectral data correlated with the reported values38. 
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            Vinyl Triflate 2.43.  To a solution of beta-keto ester 2.34 (0.256 g, 0.996 mmol) 
in tetrahydrofuran (6 mL) at –78 oC was added KHMDS (2.39 mL of 0.5M solution in 
toluene, 1.20 mmol).  The reaction mixture was warmed to –20 oC during a period of 2 h, 
then cooled the reaction mixture down to –78 oC and a solution of N-(5-chloro-2-
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pyridyl)triflimide (0.470 g in 3 mL tetrahydrofuran) was added.  The reaction continued 
stirring for 24 h in the process warming to room temperature.  The reaction was 
concentrated in vacuo.  The residue was purified by flash column chromatography (10:1 
hexanes/EtOAc + 1% Et3N) to afford 0.368 g (95%) of vinyl triflate 2.43 as a colorless 
oil.  IR (neat) 2976, 1706, 1424, 1245, 1209 cm-1; 1H-NMR (500 MHz, CDCl3) δ 4.27 (s, 
2H), 3.83 (s, 3H), 3.62 (t, J = 5.5 Hz, 2H), 2.51 (m, 2H), 1.48 (s, 9H); 13C-NMR (125 
MHz, CDCl3) δ 162.8, 153.9, 122.0, 119.5, 116.9, 114.4, 81.0, 52.3, 43.0, 39.3, 28.8, 
28.3; HRMS (ESI) m/z 390.0804 [(M+H)+ calculated for C13H19O7F3NS: 390.0834]. 
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            Vinyl Stannane 2.44.  Methyllithium (0.419 mL of 1.6 M solution in diethyl 
ether, 0.670 mmol) was added dropwise to a solution of hexamethylditin (0.804 mL of 
1.0 M solution in tetrahydrofuran, 0.804 mmol) in tetrahydrofuran (5 mL) at -30 oC under 
argon.  The reaction mixture was stirred at -30 oC for 30 min. Then the reaction was 
cooled to -65 oC and CuCN (0.030 g, 0.335 mmol) was added in the solid form.  The 
reaction mixture turned to a green-yellow solution.  
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            To a solution of vinyl bromide 2.43 (0.100 g, 0.258 mmol) in tetrahydrofuran (5 
mL) at –65 oC was added a solution of the higher order cuprate (Me3Sn)2CuCNLi2 in 
tetrahydrofuran prepared above.  The reaction continued stirring for 1 h in the process of 
warming to –20 oC.  The reaction mixture was poured into saturated sodium bicarbonate 
(10 mL) and extracted with EtOAc (4 X 10 mL).  The combined extracts were dried over 
MgSO4, filtered, and concentrated in vacuo.  The residue was purified by flash column 
chromatography (30:1 hexanes/EtOAc + 1% Et3N) to afford 0.068 g (65%) of vinyl 
stannane 2.44 as a light yellow oil.  IR (neat) 2971, 2919, 1701, 1414, 1240 cm-1; 1H-
NMR (500 MHz, CDCl3) δ 4.18 (s broad, 2H), 3.76 (s, 3H), 3.44 (t, J = 6.0 Hz, 2H), 2.50 
(m, 2H), 1.49 (s, 9H), 0.15 (s, 9H); 13C-NMR (125 MHz, CDCl3) δ 167.1, 162.1 broad, 
(154.6, 154.5), 133.2 broad, 79.7, 51.9, (44.4, 43.9), (40.5, 39.2), 33.1, 28.4, -7.6; HRMS 
(ESI) m/z 428.0868 [(M+Na)+ calculated for C15H27O4NSnNa: 428.0860]. 
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            Diene 2.45.  To a solution of vinyl stannane 2.44 (0.051 g, 0.229 mmol) and beta-
iodo enecarbamate 2.11 (0.084 g, 0.208 mmol) in DMSO (4 mL) was added Pd(Ph3P)4 
(0.024 g, 0.0208 mmol) followed by CuCl (0.103 g, 1.042 mmol) and LiCl (0.053 g, 1.25 
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mmol) and the reaction mixture was vigorously degassed (3X) by the freeze-pump-thaw 
cycles (-78 → 25 oC, Ar). The reaction mixture was heated at 80 oC for 4.5 h.  The 
reaction mixture was cooled, diluted with EtOAc (5 mL), and washed with a saturated 
sodium bicarbonate solution (10 mL).  The aqueous layers were extracted with EtOAc (3 
X 10 mL) and the combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo.  The residue was purified by flash column chromatography 
(1:1:0.5 hexanes/EtOAc/MeOH) to afford 0.048 g (69%) of diene 2.45 as a light yellow 
oil.  IR (neat) 3428 broad, 2972, 2928, 2359, 2336, 1692, 1420 cm-1; 1H-NMR (500 
MHz, CDCl3) δ 7.18 (d, J = 3.5 Hz, 1H), 5.97 (d, J = 4.5 Hz, 1H), 4.14 (s broad, 2H), 
3.72 (s, 3H), 3.50 (t, J = 5.5 Hz, 2H), 2.57 (t, J = 7.5 Hz, 2H), 2.43 (t, J = 8.0 Hz, 2H), 
2.30 (m, 2H); 13C-NMR (125 MHz, CDCl3) δ 170.8, 154.5 broad, 144.0, (132.1, 132.0), 
(128.6, 128.5), 121.7, 118.9, 80.1, 51.8, 43.9, 39.2, 30.4, 29.7, 28.4, 24.1; HRMS (ESI) 
m/z 343.1827 [(M+Li)+ calculated for C17H24N2O5Li: 343.1845]. 
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            Hydrogenation Product 2.46.  To a solution of diene 2.45 (0.033 g, 0.0985 
mmol) in ethanol (4 mL) was added palladium (5% on activated carbon, 0.021 g, 0.00985 
mmol).  The reaction mixture was placed into a Parr Shaker and shaked under 40 psi of 
hydrogen at room temperature for 36 hours.  The reaction mixture was filtered through a 
short pad of celite and washed with EtOAc (30 mL).  The filtrate was concentrated in 
vacuo.  The residue was purified by flash column chromatography (1:1:0.1 
hexanes/EtOAc/MeOH) to afford 0.029 g (87%) of hydrogenation product 2.46 as a light 
yellow oil.  IR (neat) 3421 broad, 1644, 1429, 1173 cm-1; 1H-NMR (500 MHz, DMSO, 
75 oC) δ 7.11 (s broad, 1H), 4.22 (dd, J = 13.5, 7.5 Hz, 1H), 4.03 (m, 2H), 3.59 (s, 3H), 
3.24-3.11 (m, 1H), 2.95 (t, J = 11.0 Hz, 1H), 2.89-2.83 (m, 1H), 2.75-2.62 (m, 2H), 2.20-
2.14 (m, 1H), 2.12-2.01 (m, 1H), 1.91-1.87 (m, 1H), 1.81-1.73 (m, 2H), 1.66-1.64 (m, 
1H), 1.58-1.52 (m, 1H), 1.44-1.37 (m, 1H), 1.37 (s, 9H); 13C-NMR (125 MHz, DMSO, 
75 oC) δ 173.1, (170.83, 170.78), 154.3, 79.2, (52.0, 51.8), (46.0, 45.9), (41.7, 41.6), 
41.1, 35.8, (31.0, 30.9), 29.7, 28.8, 27.9, 25.2, 25.0; HRMS (ESI) m/z 341.2 [(M+H)+ 
calculated for C17H29N2O5: 341.3]. 
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            Partially Reduced Product 2.47.  To a solution of diene 2.45 (0.078 g, 0.233 
mmol) in ethanol (8 mL) was added palladium (5% on activated carbon, 0.049 g, 0.0233 
mmol).  The reaction mixture was placed into a Parr Shaker and shaked under 40 psi of 
hydrogen at room temperature for 24 hours.  The reaction mixture was filtered through a 
short pad of celite and washed with EtOAc (40 mL).  The filtrate was concentrated in 
vacuo.  The residue was purified by flash column chromatography (1:1:0.1 
hexanes/EtOAc/MeOH) to afford 0.017 g (22%) of partially reduced product 2.47 as a 
light yellow oil contaminated with hexanes as impurity.  IR (neat) 3263 broad, 2930, 
2356, 1737, 1685, 1434 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.25 (s broad, 1H), 5.84 (d, 
J = 4.0 Hz, 1H), 4.44-4.16 (m, 2H), 3.62 (s, 3H), 3.07-2.97 (m, 1H), 2.82-2.77 (m, 2H), 
2.48-2.44 (m, 2H), 2.42-2.40 (m, 1H), 2.40-2.33 (m, 2H), 2.26-2.14 (m, 2H), 1.45 (s, 
9H); 13C-NMR (125 MHz, CDCl3) δ 172.1, 170.8, 154.6, 120.4, 118.7, 79.6, 51.4, (45.8, 
44.9), (43.0, 42.4), 41.2, 30.3, 29.7, 28.3, 24.4, 23.5; HRMS (ESI) m/z 361.1716 
[(M+Na)+ calculated for C17H26N2O5Na: 361.1739]. 
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CHAPTER III 
SUMMARY 
 
Chapter I provided background information concerning the biological activities of 
marine secondary metabolites.  We also detailed some hypotheses which have been 
proposed by several groups to account for the biogenetic origin of these structurally 
novel marine macrocyclic diamine alkaloids.  
Chapter II detailed our work towards the total synthesis of haliclonacyclamine C.  
Highlighting our synthesis is the successful use of a palladium-mediated coupling of a 
vinyl stannane and a vinyl iodide to construct the 3,4’linked bis-piperidine core structure.  
Our efforts to perform stereoselective hydrogenation of the coupled product were also 
discussed.  In addition, we described the use of a VT-NMR experiment to analyze the 
hydrogenation product and the use of molecular modeling to predict the conformation of 
some important synthetic intermediates in the total synthesis of haliclonacyclamine C.   
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APPENDIX  
SELECTED SPECTRA RELEVANT TO CHAPTER II 
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